Why choose cyclosporin A as first-line therapy in COVID-19 pneumonia
Reumatol Clin
.
2021 Nov;17(9):555-557.
doi: 10.1016/j.reuma.2020.03.001.
Epub 2020 Apr 16.
Authors
Olga Sanchez-Pernaute
1
,
Fredeswinda I Romero-Bueno
1
,
Albert Selva-O'Callaghan
2
Affiliations
1
Rheumatology Division, Jiménez Díaz Foundation University Hospital and Health Research Institute, Universidad Autónoma de Madrid, Madrid, Spain.
2
Department of Internal Medicine, Hospital Universitari Val d'Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain.
PMID:
32354685
PMCID:
PMC7160056
DOI:
10.1016/j.reuma.2020.03.001
No abstract available